GB2424185A - Cough mixture comprising codeine linctus and guaifenesin - Google Patents

Cough mixture comprising codeine linctus and guaifenesin Download PDF

Info

Publication number
GB2424185A
GB2424185A GB0505392A GB0505392A GB2424185A GB 2424185 A GB2424185 A GB 2424185A GB 0505392 A GB0505392 A GB 0505392A GB 0505392 A GB0505392 A GB 0505392A GB 2424185 A GB2424185 A GB 2424185A
Authority
GB
United Kingdom
Prior art keywords
cough
linctus
guaifenesin
codeine
cough mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0505392A
Other versions
GB2424185B (en
GB0505392D0 (en
Inventor
Atulkumar Sumanbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0505392A priority Critical patent/GB2424185B/en
Publication of GB0505392D0 publication Critical patent/GB0505392D0/en
Publication of GB2424185A publication Critical patent/GB2424185A/en
Application granted granted Critical
Publication of GB2424185B publication Critical patent/GB2424185B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A cough mixture comprising codeine linctus and guaifenesin. The mixture may additionally comprise pseudoephedrine hydrochloride, promethazine and/or ipecacuanha tincture. The mixture may additionally comprise flavouring, especially strawberry flavouring, menthol and/or a preservative. The cough mixture may also comprise a sugar-free base syrup. The cough mixture is particularly suitable for a dry cough and/or persistent cough and is suitable for adults or children.

Description

A COUGH MIXTURE
This invention relates to a cough mixture and, more especially, this invention relates to a cough mixture for a dry cough.
There are various different types of coughs such for example as coughs which are known as dry coughs and coughs which are known as night time coughs. There are many different types of known cough mixtures for each type of cough. Some of the known cough mixtures are more effective than others.
It is an aim of the present invention to provide a new mixture which is for a dry cough and which is effective.
Accordingly, in one non-limiting embodiment of the present invention a cough mixture comprising codeine linctus BP and guaifenesin.
The cough mixture of the present invention is able to be formulated for use by children and adults.
The cough mixture may be one which is for a child, in which the codeine linctus BP is in the form of codeine paediatric linctus BP, and in which the guaifenesin is in the form of guaifenesin Ph Eur. This cough mixture is suitable for a child with a dry cough.
The above cough mixture for the child with a dry cough may be one comprising per 5ml of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg Alternatively, the cough mixture may be one which is for a child, in which the codeine linctus BP is in the form of codeine paediatric linctus BP, in which the guaifenesin is in the form of guaifenesin Ph Eur, and in which the cough mixture includes pseudophedrine Hcl. Such a cough mixture is suitable for a child with a dry plus cough, i.e. a very persistent cough.
The above mentioned cough mixture for a child with a dry plus cough may be one which comprises per 5ml of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg pseudophedrine Hcl 30mg Alternatively, the cough mixture may be one which is for a child, in which the codeine linctus BP is in the form of codeine paediatric linctus BP, in which the guaifenesin is in the form of guaifenesin, and in which the cough mixture includes promethazine. Such a cough mixture is suitable for a child with a night time cough.
The above cough mixture for a child with a night time cough may be one which comprises per 5ml of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg promethazine 2mg All of the above mentioned cough mixtures for a child may advantageously include a flavouring. A presently preferred flavouring is a strawberry flavouring. Other types of flavouring may however be employed so that, for example, the flavouring may be lemon or peppermint.
Alternatively, the cough mixture may be one which is for an adult, in which the codeine linctus BP is in the form of codeine linctus BP, in which the guaifenesin is in the form of guaifenesin Ph Eur, and in which the cough mixture include ipecacuanha tincture. Such a cough mixture is suitable for an adult with a dry cough.
The cough mixture for the adult with a dry cough may be one in which comprise per 5m1 of total solution: codeine linctus BP 15mg guaifenesin Ph Eur 100mg ipecacuanha tincture BP 3ml Alternatively, the cough mixture may be one which is for an adult, in which the codeine linctus BP is in the form of codeine linctus BP, in which the guaifenesin is in the form of guaifenesin Ph Eur, and in which the cough mixture includes ipecacuanha tincture, pseudophedrine HcI, and menthol.
Such a cough mixture is suitable for an adult with a dry cough plus the need for decongestion.
The above cough mixture for an adult with a dry cough plus the need for decongestion may be one which comprises per 5m1 of total solution: codeine linctus BP 15mg (15mg - 3Omg/5m1) guaifenesin Ph Eur 100mg ipecacuanha tincture BP 3ml pseudophedrine Hcl 60mg (30mg - 60mg) menthol 2.5mg In all of the cough mixtures of the present invention, there may be included at least one sugar-free base syrup. In all of the cough mixtures of the present invention, there may be included at least one preservative.
Embodiments of the invention will now be described with reference to the accompanying Examples.
EXAMPLE I
There was formulated a cough mixture which was for a child with a dry cough and which comprises per 5m1 of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg strawberry flavouring a sugar-free base syrup a preservative The child was treated with the cough mixture for a period of days until the dry cough disappeared. During the treatment, the dry cough was kept under control to the benefit of the child.
EXAMPLE II
There was formulated a cough mixture which was for a child with a dry plus cough and which comprises per 5ml of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg pseudophedrine Hcl 30mg strawberry flavouring a sugar-free base syrup a preservative The child was treated with the cough mixture for a period of days until the dry plus cough disappeared. During the treatment, the dry plus cough was kept under control to the benefit of the child.
EXAMPLE III
There was formulated a cough mixture which was for a child with a nighttime cough and which comprises per 5m1 of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg promethazine 2mg strawberry flavouring a sugar-free base syrup a preservative The child was treated with the cough mixture for a period of days until the night- time cough disappeared. During the treatment, the night-time cough was kept under control to the benefit of the child.
EXAMPLE IV
There was formulated a cough mixture which was for an adult with a dry cough and which comprises per 5m1 of total solution: codeine linctus BP 15mg guaifenesin Ph Eur 100mg ipecacuanha tincture BP 3m1 The adult was treated with the cough mixture for a period of days until the dry cough disappeared. During the treatment, the dry cough was kept under control to the benefit of the adult.
EXAMPLE V
There was formulated a cough mixture which was for an adult with a dry cough and a need for decongestion and which comprises per 5ml of total solution: codeine linctus BP 15mg (15mg - 3Omg/5ml) guaifenesin Ph Eur 100mg ipecacuanha tincture BP 3m1 pseudophedrine Hcl 60mg (30mg - 60mg) menthol 2.5mg The adult was treated with the cough mixture for a period of days until the dry cough and the need for decongestion disappeared. During the treatment, the dry cough and the need for decongestion were kept under control to the benefit of the adult.
It is to be appreciated that the embodiments of the invention described above with reference to the Examples have been given by way of example only and that modifications may be effected. Thus, for example, the cough mixtures for a child may have a flavouring other than strawberry.
The adult cough mixtures do not have flavourings but they may have flavourings if desired. More than one sugar-free base syrup and more than one preservative may be employed.

Claims (16)

1. A cough mixture comprising codeine linctus BP and guaifenesin.
2. A cough mixture according to claim I which is for a child, in which the codeine linctus BP is in the form of codeine paediatric linctus BP, and in which the guaifenesin is in the form of guaifenesin Ph Eur.
3. A cough mixture according to claim 2 comprising per 5m1 of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg
4. A cough formulation according to claim I which is for a child, in which the codeine linctus BP is in the form of codeine paediatric linctus BP, in which the guaifenesin is in the form of guaifenesin Ph Eur, and in which the cough mixture includes pseudophedrine Hcl.
5. A cough mixture according to claim 4 which comprises per 5m1 of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg pseudophedrine Hcl 30mg
6. A cough mixture according to claim I which is for a child, in which the codeine linctus Bp is in the form of codeine paediatic linctus BP, in which the guaifenesin is in the form of guaifenesin, and in which the cough mixture includes promethazine.
7. A cough mixture according to claim 6 and which comprises per 5m1 of total solution: codeine paediatric linctus BP 3mg guaifenesin Ph Eur 50mg promethazine 2mg
8. A cough mixture according to any one of claims 2 -7 and including a flavouring.
9. A cough mixture according to claim 8 in which the flavouring is a strawberry flavouring.
10. A cough mixture according to claim I which is for an adult, in which the codeine linctus BP is in the form of codeine linctus BP, in which the guaifenesin is in the form of guaifenesin Ph Eur, and in which the cough mixture includes ipecacuanha tincture.
II. A cough mixture according to claim 10 and which comprise per 5m1 of total solution: codeine linctus BP 15mg guaifenesin Ph Eur 100mg ipecacuanha tincture BP 3m1
12. A cough mixture according to claim I which is for an adult, in which the codeine linctus BP is in the form of codeine linctus BP, in which the guaifenesin is in the form of guaifenesin Ph Eur, and in which the cough mixture includes ipecacuanha tincture, pseudophedrine Hcl, and menthol.
13. A cough mixture according to claim 12 and which comprises per 5m1 of total solution: codeine adult linctus BP 15mg (15mg - 3Omg/5m1) guaifenesin Ph Eur 100mg ipecacuanha tincture BP 3m1 pseudophedrine Hcl 60mg (30mg - 60mg) menthol 2.5mg
14. A cough mixture according to any one of the preceding claims and including at least one sugar-free base syrup.
15. A cough mixture according to any one of the preceding claims and including at least one preservative.
16. A cough mixture substantially as herein described with reference to the accompanying Examples.
GB0505392A 2005-03-16 2005-03-16 A cough mixture Expired - Fee Related GB2424185B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0505392A GB2424185B (en) 2005-03-16 2005-03-16 A cough mixture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0505392A GB2424185B (en) 2005-03-16 2005-03-16 A cough mixture

Publications (3)

Publication Number Publication Date
GB0505392D0 GB0505392D0 (en) 2005-04-20
GB2424185A true GB2424185A (en) 2006-09-20
GB2424185B GB2424185B (en) 2009-12-30

Family

ID=34509162

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0505392A Expired - Fee Related GB2424185B (en) 2005-03-16 2005-03-16 A cough mixture

Country Status (1)

Country Link
GB (1) GB2424185B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012025761A1 (en) * 2010-08-27 2012-03-01 Biocopea Limited Theobromine in combination with an expectorant or a mucolytic for use in therapy
US8703158B2 (en) 2009-06-16 2014-04-22 Biocopea Limited Theobromine for the treatment of cough
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065988A2 (en) * 2002-02-04 2003-08-14 Pharmacia Corporation A combination for treating cold and cough

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002308761A (en) * 2001-04-09 2002-10-23 Taisho Pharmaceut Co Ltd Antitussive agent for common cold
WO2003068206A1 (en) * 2002-02-13 2003-08-21 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising terbutaline or salbutamol in combination with guaiphenesine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065988A2 (en) * 2002-02-04 2003-08-14 Pharmacia Corporation A combination for treating cold and cough

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Martindale, The Extra Pharmacopoeia, 31st Edition, 1999, (James E.F. Reynolds) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703158B2 (en) 2009-06-16 2014-04-22 Biocopea Limited Theobromine for the treatment of cough
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
WO2012025761A1 (en) * 2010-08-27 2012-03-01 Biocopea Limited Theobromine in combination with an expectorant or a mucolytic for use in therapy
JP2013536257A (en) * 2010-08-27 2013-09-19 バイオコピア リミテッド Theobromine in combination with expectorants or mucolytic agents for use in therapy
JP2016196504A (en) * 2010-08-27 2016-11-24 バイオコピア リミテッドＢｉｏｃｏｐｅａ Ｌｉｍｉｔｅｄ Theobromine in combination with expectorant or mucolytic for use in therapy

Also Published As

Publication number Publication date
GB2424185B (en) 2009-12-30
GB0505392D0 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
EA200400471A1 (en) ORAL DOSED FORM PROPIVERINA
ATE218582T1 (en) CYCLOSPORINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
WO2002000201A3 (en) Method for preparing a composition
BRPI0608453A2 (en) compounds having activity in the correction of mutant cftr processing and uses of these
BR0111016A (en) Sustained-release pharmaceutical compositions for parenteral administration of biologically active hydrophilic compounds
BRPI0408681A (en) compounds, pharmaceutical compositions, use of a 1,2,3,4-tetrahydroisoquinoline derivative, method for treating or preventing disease, process for the manufacture of pharmaceutical compositions, and use of one or more compounds
CY1105931T1 (en) USE OF AN ESTROGEN AGENT/ANTIGATOR TO TREAT FEMALE SEXUAL DYSFUNCTION
BRPI0009299B8 (en) mechanically stable pharmaceutical administration forms for oral administration, and, process for producing mechanically stable pharmaceutical administration forms.
EA200000584A3 (en) Solid thermoformable controlled-release pharmaceutical composition
GB2424185A (en) Cough mixture comprising codeine linctus and guaifenesin
ATE522251T1 (en) TOILET ARTICLE CONTAINING AN ORDERED ACTIVE ACTIVE PREPARATION AND AN ADMINISTRATION VEHICLE
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
DK1256343T3 (en) Flibanserin for the treatment of extrapyramidal movement disorders
HUP0301972A2 (en) Active substance combination containing an opioid having a fentanyl-type structure and ketamine and pharmaceutical compositions containing it
ATE218580T1 (en) CYCLOSPORINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
BR9914718A (en) Controlled release pharmaceutical formulations comprising a pde-5 cgmp inhibitor
NO20071354L (en) use of the same Butylphthalide self-emulsifying drug delivery system, as well as methods of preparing and using the same.
BR0210261A (en) Pharmaceutical formulations for the efficient administration of apomorphine, 6ar - (-) - n-propyl norapomorphine and their derivatives and prodrugs thereof
RS50768B (en) Dosage regimen and pharmaceutical composition for emergency contraception
BR0207978A (en) N-but-3enyl norbuprenorphine and methods of use
CY1107819T1 (en) PHARMACEUTICAL FORM OF OLANZAPIN
CY1105168T1 (en) BIPHASIC COMPOSITION WITH TRAMADOL
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
BR0116060A (en) Dronedarone pharmaceutical composition for parenteral administration
AR046226A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING FLAVOR WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20110316